G-1: Selective GPR30 Agonist Powering Cardiovascular & Cancer Research

Principle Overview: Unlocking the Power of a Selective G Protein-Coupled Estrogen Receptor Agonist

G-1 (CAS 881639-98-1) is a potent and selective agonist for the G protein-coupled estrogen receptor GPR30 (also known as GPER1), a non-classical estrogen receptor localized primarily to the endoplasmic reticulum. Unlike classical estrogen receptors (ERα and ERβ), GPR30 mediates rapid, non-genomic signaling events, making G-1 an invaluable chemical agonist for dissecting estrogen receptor independent signaling pathways. With a high binding affinity (Ki ≈ 11 nM) and negligible off-target activity at classical estrogen receptors even at micromolar concentrations, G-1 is trusted for experiments requiring uncompromised receptor selectivity.

Upon GPR30 activation, G-1 triggers a cascade of intracellular events, including elevation of intracellular calcium (EC50 = 2 nM), PI3K-dependent nuclear accumulation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3), and downstream modulation of the PI3K/Akt/mTOR signaling pathway. These mechanisms underpin its utility in cardiovascular research, breast cancer research, and emerging applications in neuropathic pain modulation.

Step-by-Step Experimental Workflow: Enhancing Reproducibility with G-1

1. Preparation of Stock Solutions and Handling

• G-1 is supplied as a crystalline solid (MW 412.28, C21H18BrNO3), DMSO soluble at ≥41.2 mg/mL, but insoluble in water and ethanol.
• For optimal performance, prepare concentrated stock solutions in DMSO at >10 mM. Gently warm and sonicate the solution to ensure complete dissolution.
• Store aliquots at -20°C, minimizing freeze-thaw cycles to preserve activity. Use freshly thawed aliquots promptly.

2. In Vitro Applications

• Breast Cancer Cell Migration Assays: G-1 inhibits migration of SKBr3 and MCF7 cells with remarkable potency (IC50 = 0.7 nM and 1.6 nM, respectively). For migration or invasion assays, titrate G-1 across nanomolar ranges to determine optimal inhibitory concentrations.
• Intracellular Calcium Imaging: Employ calcium-sensitive dyes (e.g., Fluo-4 AM) to visualize rapid calcium signaling following GPR30 activation. Use real-time imaging systems to quantify EC50 responses (~2 nM for calcium elevation).
• PI3K Signaling Assays: Monitor nuclear PIP3 accumulation and downstream Akt/mTOR phosphorylation using immunoblotting or immunofluorescence. Include G-1 as a positive control to validate GPR30-mediated PI3K pathway activation.

3. In Vivo Protocols

• Cardiac Fibrosis & Heart Failure Models: In female Sprague-Dawley rats with bilateral ovariectomy and induced heart failure, chronic administration of G-1 (120 μg/kg daily, 14 days) reduces brain natriuretic peptide levels, inhibits cardiac fibrosis, and improves cardiac contractility by regulating β1- and β2-adrenergic receptor expression.
• Neuropathic Pain Models: Recent studies, such as Chen, Wu, Xie et al., 2024, have used G-1 to interrogate the role of GPR30 in spinal cholecystokinin-positive (CCK+) neurons. These protocols typically employ intrathecal or local spinal administration, with behavioral assays (mechanical allodynia, thermal hyperalgesia) to assess functional outcomes.

Advanced Applications and Comparative Advantages

1. Cardiovascular Research: Cardiac Fibrosis Attenuation and Heart Failure Models

G-1's profound efficacy in heart failure animal models is anchored in its ability to selectively activate GPR30, leading to inhibition of cardiac fibrosis and normalization of β-adrenergic receptor expression. Chronic G-1 treatment not only reduces fibrotic remodeling but also restores contractile function, making it a unique cardioprotective agent in research. These outcomes are corroborated in "G-1: Selective GPR30 Agonist Empowering Cardiovascular and Oncology Research", which highlights its translational potential for heart failure treatment research and cardiovascular disease modeling.

2. Breast Cancer Research: Inhibition of Cell Migration and Beyond

In oncology, G-1's selectivity for GPR30 enables researchers to dissect GPR30-mediated signaling pathways, distinct from classical estrogen receptor effects. Its sub-nanomolar inhibition of SKBr3 and low-nanomolar inhibition of MCF7 cell migration underscores its value for studies on GPR30 agonist for chemoprevention and breast cancer cell migration inhibition. For a practical guide to cell-based workflows, "Empowering Cell Assays with G-1" provides troubleshooting and optimization tips that complement this article's protocol focus.

3. Neuropathic Pain Modulation: New Frontiers in GPR30-Targeted Research

The reference study (Chen, Wu, Xie et al., 2024) demonstrates GPR30's pivotal role in spinal CCK+ neurons and S1–SDH post-synaptic neurons, modulating neuropathic pain via GPR30-mediated PI3K signaling pathway and intracellular calcium elevation. Inhibition or chemogenetic modulation of GPR30 in these neurons reverses mechanical allodynia and hyperalgesia, directly linking GPR30 activation to pain circuitry. This work extends the applications of G-1 beyond cardiovascular and cancer biology into the realm of neurobiology, establishing its relevance in GPR30 in neuropathic pain modulation.

4. Comparative Literature Landscape

For a mechanistically rich exploration, "Unlocking the Translational Power of G-1" complements this guide by delving into GPR30 in endocrine research and immune modulation. Meanwhile, "Unraveling GPR30 Signaling in Cardiology and Oncology" provides advanced strategies and contrasts the effects of G-1 against classical estrogen ligands, supporting the case for G-1 as a GPR30 selective ligand with robust translational utility.

Troubleshooting & Optimization Tips: Maximizing G-1 Performance

• Solubility: G-1 is highly soluble in DMSO but insoluble in water and ethanol. For high-concentration stocks (>10 mM), combine warming (37°C) and brief sonication to ensure complete dissolution. Avoid prolonged exposure to room temperature and repeated freeze-thaw cycles.
• Stock Stability: Store DMSO stocks at -20°C in tightly sealed aliquots. Use blue ice during shipment and minimize exposure to moisture, as hydrolysis or oxidation can degrade reagent quality.
• Receptor Selectivity: Verify experimental specificity by including appropriate controls (e.g., ERα/ERβ antagonists, GPR30 knockdown or knockout models). G-1's minimal activity at classical estrogen receptors ensures that observed effects are driven by GPR30 activation.
• Assay Timing: For acute signaling studies (e.g., intracellular calcium elevation), rapid addition and real-time readout are critical. For chronic studies (e.g., cardiac fibrosis attenuation), adhere to validated dosing regimens (e.g., 120 μg/kg daily for 14 days in rats).
• Batch-to-Batch Consistency: Sourcing from reputable suppliers like APExBIO ensures lot-to-lot consistency, purity, and quality control, mitigating common issues seen with generic vendors.
• Data Interpretation: Normalize data to vehicle (DMSO) controls and consider off-target screening for new cell lines or animal models, especially when extending G-1 use to novel systems.

Future Outlook: Expanding the Frontiers of GPR30-Targeted Discovery

With the growing recognition of GPR30 as a therapeutic target in cardiovascular, oncologic, and neurobiological disease models, G-1 (CAS 881639-98-1), a selective GPR30 agonist from APExBIO, is poised to accelerate discoveries in rapid estrogen signaling, chemoprevention, cardiac fibrosis inhibition, and neuropathic pain research. The unique combination of high receptor selectivity, robust in vitro and in vivo efficacy, and reliable solubility profile positions G-1 as a cornerstone reagent for next-generation studies of GPR30-mediated signaling pathways.

Looking ahead, the integration of G-1 in multi-omics platforms, high-throughput screening, and translational disease models will deepen our understanding of G protein-coupled estrogen receptor agonist functions across diverse biological contexts. As new research, such as Chen, Wu, Xie et al. (2024), continues to reveal GPR30's impact on neural circuitry and pain modulation, the demand for reliable, selective ligands like G-1 will only accelerate.

For detailed product specifications and ordering information, visit the G-1 (CAS 881639-98-1), a selective GPR30 agonist page at APExBIO, your trusted supplier for high-performance chemical agonists supporting breakthrough cardiovascular, cancer, and neuroscience research.